PharmStars Spring 2025 Accelerator

Global Key Solutions Celebrates PharmStars Spring 2025 Accelerator Graduation

We’re proud to announce that Global Key Solutions has successfully completed the Spring 2025 PharmStars Accelerator! As one of the 12 digital health startups selected, GKSC participated in the industry’s premier pharma-focused accelerator designed to foster innovation and strategic partnerships between startups and the pharmaceutical sector.

PharmStars officially announced the Spring 2025 cohort graduates in a press release.

The program offered exclusive opportunities for mentorship, education, and direct engagement with leading pharmaceutical firms. Over the course of several months, we refined our go-to-market strategy, aligned our product roadmap with pharma pain points, and formed valuable new partnerships.

“The activities within the PharmStars program elevated the startups to truly understand the pharmaceutical landscape. I was impressed to see the dedication, maturity, and scale of all the cohort companies.”
— Dr. Ligia Zubik, advisor invited to the program by the Global Key Solutions team

What This Means for GKSC

Ensuring the delivery of high-quality medicines and health products has never been more critical. Beyond the traditional pressures of passing FDA inspections, companies are now expected to contribute to broader national security objectives and supply chain resilience through excellence in quality.

At Global Key Solutions, this is our mission. Completing the PharmStars accelerator reinforced the urgency and importance of innovating at the intersection of compliance, data, and pharmaceutical performance.

GKS Messaging Developed with PharmStars

Tagline

Continuously Updated Information Engine to Access Industry-Wide Compliance and Regulatory Data

Company Description

Pharmaceutical companies face increasing regulatory pressure beyond routine inspections. The issuance rate of enforcement actions like FDA 483s and Warning Letters has doubled since 2019. Vigilant monitoring and proactive strategies are essential to stay compliant with shifting regulatory expectations. While regulatory, compliance, and quality data is available, it is often fragmented, outdated, lacks context, and is difficult to synthesize into actionable information.

Our proprietary engine unifies regulatory and compliance data across the FDA-regulated landscape, providing searchable and actionable insights for quality, operations, and leadership teams. Built by a team of former FDA reviewers and global quality leaders, our engine contains over 5,000 charts, 12,000 documents, and 300,000+ inspection observations and citations, all systematically categorized and continuously updated. A top 10 drug and device manufacturer is using our platform to develop data-driven compliance plans, including preventive strategy, continuous improvements, Root Cause Analysis (RCA), and effective Corrective and Preventive Actions.

Our information engine has also been used to prepare for FDA inspections and audits. In 2025, we will add document citation capabilities, which will recommend updates to internal regulatory documents and workflows whenever FDA policies are revised.

Stay tuned for more partnership news coming soon!